Srinivas Akkaraju - Jun 5, 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Stock Option (right to buy)	Award	$0	+6K		$0.00	6K	Jun 5, 2024	Common Stock	6K	$5.30	Direct	F1
transaction	SYRS	Restricted Stock Units	Award	$0	+4K		$0.00	4K	Jun 5, 2024	Common Stock	4K		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
F2	Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3	These RSUs will vest in their entirety on the earlier to occur of (i) the first anniversary of the date of grant of the award, or (ii) the date of the Company's next Annual Meeting of Stockholders, subject in each case to the director's continued service as a director through the applicable vesting date.